Risk-Reducing Mastectomy in BRCA1/2 and Other High-Risk Gene Carriers: Current Evidence and Practical Guidance
Open Access
- 1 January 2026
- journal article
- review article
- Published by XMLink in Journal of Breast Cancer
- Vol. 29 (1) , 1-16
Abstract
Lee JH, et al. J Breast Cancer. 2025 Dec;29:e3. https://doi.org/10.4048/jbc.2025.0279Keywords
This publication has 61 references indexed in Scilit:
- MRI Surveillance and Breast Cancer Mortality in Women With BRCA1 and BRCA2 Sequence VariationsJAMA Oncology, 2024
- Comparison of CDH1 Penetrance Estimates in Clinically Ascertained Families vs Families Ascertained for Multiple Gastric CancersJAMA Oncology, 2019
- Associations Between Cancer Predisposition Testing Panel Genes and Breast CancerJAMA Oncology, 2017
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation CarriersJAMA, 2017
- Effect of Oophorectomy on Survival After Breast Cancer inBRCA1andBRCA2Mutation CarriersJAMA Oncology, 2015
- Association of Risk-Reducing Surgery in BRCA1 or BRCA2 Mutation Carriers With Cancer Risk and MortalityJAMA, 2010
- Founder and Recurrent CDH1 Mutations in Families With Hereditary Diffuse Gastric CancerJAMA, 2007
- Effects of Tamoxifen vs Raloxifene on the Risk of Developing Invasive Breast Cancer and Other Disease OutcomesThe NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 TrialJAMA, 2006
- Surveillance of BRCA1 and BRCA2 Mutation Carriers With Magnetic Resonance Imaging, Ultrasound, Mammography, and Clinical Breast ExaminationJAMA, 2004
- Tamoxifen and Breast Cancer Incidence Among Women With Inherited Mutations in BRCA1 and BRCA2JAMA, 2001